MX2021006951A - Formas cristalinas y formas de sal de un inhibidor de cinasa. - Google Patents
Formas cristalinas y formas de sal de un inhibidor de cinasa.Info
- Publication number
- MX2021006951A MX2021006951A MX2021006951A MX2021006951A MX2021006951A MX 2021006951 A MX2021006951 A MX 2021006951A MX 2021006951 A MX2021006951 A MX 2021006951A MX 2021006951 A MX2021006951 A MX 2021006951A MX 2021006951 A MX2021006951 A MX 2021006951A
- Authority
- MX
- Mexico
- Prior art keywords
- forms
- relates
- kinase inhibitor
- crystalline forms
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a formas cristalinas de la base libre del inhibidor de c-Met, Compuesto 1. La invención también se refiere a formas cristalinas de sales del Compuesto 1. La invención también se refiere a composiciones farmacéuticas que comprenden los polimorfos sólidos de la base libre y sales del Compuesto 1. La invención se refiere además a métodos para tratar una enfermedad, trastorno o síndrome mediado al menos en parte por la modulación de la actividad in vivo de una proteína cinasa.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779430P | 2018-12-13 | 2018-12-13 | |
| US201962856469P | 2019-06-03 | 2019-06-03 | |
| PCT/US2019/065972 WO2020123800A1 (en) | 2018-12-13 | 2019-12-12 | Crystalline forms and salt forms of a kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021006951A true MX2021006951A (es) | 2021-07-15 |
Family
ID=69160358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021006951A MX2021006951A (es) | 2018-12-13 | 2019-12-12 | Formas cristalinas y formas de sal de un inhibidor de cinasa. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20230029213A1 (es) |
| EP (1) | EP3894012A1 (es) |
| JP (2) | JP2022512399A (es) |
| KR (1) | KR20210102381A (es) |
| CN (1) | CN113329790A (es) |
| AU (1) | AU2019395419A1 (es) |
| BR (1) | BR112021011333A2 (es) |
| CA (1) | CA3122840A1 (es) |
| CL (1) | CL2021001537A1 (es) |
| CO (1) | CO2021007613A2 (es) |
| CR (1) | CR20210375A (es) |
| GE (1) | GEP20247596B (es) |
| IL (1) | IL283860A (es) |
| MA (1) | MA54458A (es) |
| MX (1) | MX2021006951A (es) |
| PE (1) | PE20211757A1 (es) |
| PH (1) | PH12021551356A1 (es) |
| SG (1) | SG11202105949RA (es) |
| TW (1) | TW202039440A (es) |
| WO (1) | WO2020123800A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20200358A (es) * | 2018-01-26 | 2021-02-22 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de cinasas |
| US20230192619A1 (en) * | 2020-04-30 | 2023-06-22 | Exelixis, Inc. | Processes for the Preparation of a Kinase Inhibitor |
| MX2023001298A (es) | 2020-07-31 | 2023-02-22 | Exelixis Inc | Combinaciones para el tratamiento de cancer. |
| CA3196001A1 (en) | 2020-11-05 | 2022-05-12 | Exelixis, Inc. | Pharmaceutical compositions of a kinase inhibitor |
| CN112650176B (zh) * | 2020-12-22 | 2022-08-30 | 天能化工有限公司 | 一种盐酸解析开停车工序的dcs控制方法 |
| TW202334090A (zh) * | 2021-11-03 | 2023-09-01 | 美商艾克塞里克斯公司 | 用於治療激酶依賴性病症之化合物 |
| WO2023122739A1 (en) | 2021-12-22 | 2023-06-29 | Exelixis, Inc. | Crystalline forms and salt forms of a kinase inhibitor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2213661T1 (sl) * | 2003-09-26 | 2011-11-30 | Exelixis Inc | c-Met modulatorji in postopki uporabe |
| JP5039027B2 (ja) | 2005-04-15 | 2012-10-03 | ネオジェニックス オンコロジー， インコーポレイテッド | 結腸癌および膵臓癌のための、組換え型モノクローナル抗体および対応する抗原 |
| CN107892719B (zh) | 2012-10-04 | 2022-01-14 | 达纳－法伯癌症研究所公司 | 人单克隆抗-pd-l1抗体和使用方法 |
| SG11201508528TA (en) | 2013-05-02 | 2015-11-27 | Anaptysbio Inc | Antibodies directed against programmed death-1 (pd-1) |
| CR20200358A (es) * | 2018-01-26 | 2021-02-22 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de cinasas |
| WO2020247019A1 (en) * | 2019-06-03 | 2020-12-10 | Exelixis, Inc. | Crystalline salt forms of a kinase inhibitor |
-
2019
- 2019-12-12 CN CN201980090041.5A patent/CN113329790A/zh active Pending
- 2019-12-12 KR KR1020217021734A patent/KR20210102381A/ko unknown
- 2019-12-12 AU AU2019395419A patent/AU2019395419A1/en active Pending
- 2019-12-12 EP EP19836338.4A patent/EP3894012A1/en active Pending
- 2019-12-12 MX MX2021006951A patent/MX2021006951A/es unknown
- 2019-12-12 CA CA3122840A patent/CA3122840A1/en active Pending
- 2019-12-12 PE PE2021000862A patent/PE20211757A1/es unknown
- 2019-12-12 JP JP2021533537A patent/JP2022512399A/ja active Pending
- 2019-12-12 BR BR112021011333-9A patent/BR112021011333A2/pt unknown
- 2019-12-12 GE GEAP201915695A patent/GEP20247596B/en unknown
- 2019-12-12 CR CR20210375A patent/CR20210375A/es unknown
- 2019-12-12 WO PCT/US2019/065972 patent/WO2020123800A1/en active Application Filing
- 2019-12-12 US US17/312,658 patent/US20230029213A1/en active Pending
- 2019-12-12 SG SG11202105949RA patent/SG11202105949RA/en unknown
- 2019-12-12 MA MA054458A patent/MA54458A/fr unknown
- 2019-12-13 TW TW108145868A patent/TW202039440A/zh unknown
-
2021
- 2021-06-09 IL IL283860A patent/IL283860A/en unknown
- 2021-06-09 PH PH12021551356A patent/PH12021551356A1/en unknown
- 2021-06-10 CO CONC2021/0007613A patent/CO2021007613A2/es unknown
- 2021-06-11 CL CL2021001537A patent/CL2021001537A1/es unknown
-
2023
- 2023-12-27 JP JP2023221085A patent/JP2024038167A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GEP20247596B (en) | 2024-02-26 |
| CO2021007613A2 (es) | 2021-06-21 |
| BR112021011333A2 (pt) | 2021-08-31 |
| WO2020123800A1 (en) | 2020-06-18 |
| IL283860A (en) | 2021-07-29 |
| PE20211757A1 (es) | 2021-09-07 |
| MA54458A (fr) | 2021-10-20 |
| JP2024038167A (ja) | 2024-03-19 |
| EP3894012A1 (en) | 2021-10-20 |
| KR20210102381A (ko) | 2021-08-19 |
| CN113329790A (zh) | 2021-08-31 |
| JP2022512399A (ja) | 2022-02-03 |
| US20230029213A1 (en) | 2023-01-26 |
| CR20210375A (es) | 2021-08-18 |
| CA3122840A1 (en) | 2020-06-18 |
| AU2019395419A1 (en) | 2021-07-01 |
| TW202039440A (zh) | 2020-11-01 |
| SG11202105949RA (en) | 2021-07-29 |
| CL2021001537A1 (es) | 2022-02-04 |
| PH12021551356A1 (en) | 2021-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021006951A (es) | Formas cristalinas y formas de sal de un inhibidor de cinasa. | |
| EA201792214A1 (ru) | Соединения замещенного хиназолина | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| MX2021014773A (es) | Formas de sales cristalinas de un inhibidor de cinasas. | |
| PH12020552187A1 (en) | Pcsk9 antagonist compounds | |
| EA201690752A1 (ru) | Ингибиторы g12c kras | |
| EA201991884A3 (ru) | Ингибиторы g12c kras | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| PH12020550881A1 (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
| EA201890086A1 (ru) | 1,4-замещенные производные пиперидина | |
| EA200702339A1 (ru) | Замещенные амидные производные в качестве ингибиторов протеинкиназы | |
| EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| MX2023010303A (es) | Metodo de modulacion de las vias de se?alizacion de tigit y pd-1 mediante el uso de compuestos de 1,2,4-oxadiazol. | |
| PH12019502868A1 (en) | Composition for injection | |
| MX2021012105A (es) | Compuestos de pirrol. | |
| EA201992744A1 (ru) | Фармацевтические композиции n-(2-(2-(диметиламино)этокси)-4-метокси-5-((4-(1-метил-1h-индол-3-ил)пиримидин-2-ил)амино)фенил)акриламида и его солей | |
| MX2023005273A (es) | Composiciones farmaceuticas de un inhibidor de cinasa. | |
| PH12019501566A1 (en) | Amide compounds and use thereof | |
| MX2021012248A (es) | Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos. | |
| CY1123185T1 (el) | Παραγωγα ινδολιου | |
| EA202191653A1 (ru) | Кристаллические формы и солевые формы ингибитора киназы | |
| MX2021014228A (es) | Formas cristalinas de sal de n-(4-(4 (ciclopropilmetil)piperazin 1- carbonil)fenil)quinolin-8-sulfonamida. | |
| EA202192760A1 (ru) | Трициклические соединения | |
| EA202190452A1 (ru) | Ингибиторы cdk8/19 |